

8 July 2019

Diaceutics PLC
("Diaceutics" or the "Company")

Trading update

Diaceutics PLC (AIM: DXRX), a provider of data analytics and implementation services to the global pharmaceutical industry, announces a trading update for the six months ended 30 June 2019. Trading has continued in line with market expectations and the Company remains well positioned in key markets, underpinned by a strong sales performance.

An increased international footprint has enhanced Diaceutics' global offering and allowed the Company to acquire new international clients. The Nexus project is progressing as planned.

All outstanding debt has now been retired from the balance sheet resulting in net cash of £14.0m.

The Group's interim results are expected to be announced in early September.

Enquiries:

Diaceutics PLC

Peter Keeling, Chief Executive Officer
Philip White, Chief Financial Officer

www.diaceutics.com
via Walbrook PR

Cenkos Securities plc (Nominated adviser and broker)

Callum Davidson / Giles Balleny
Michael Johnson (Sales)

+44 (0) 20 3861 6630

Walbrook PR

Anna Dunphy
Paul McManus

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Mob: +44 (0)7876 741 001
Mob: +44 (0)7980 541 893

About Diaceutics

Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TSTUGUQAMUPBURQ